Make sense of a disrupted world
Add this topic to your myFT Digest for news straight to your inbox
Platform drops nine separate fees following regulatory crackdown
Neil Woodford’s biotech play takes a significant down round.
The Adventurous Investor senses there could be future value in spinout specialists
Listed investment company says sentiment hit by difficulties at manager’s flagship fund
US bank to have final say on investment choices under new terms of £150m overdraft
Steven Harris to step down from Woodford Patient Capital in latest shake-up
Move prompted by ‘reassessment of the current progress of the business’
£32bn sitting in poorly performing ‘dog’ funds, report reveals
Increase in net inflows comes amid concerns about controversial ‘best buy’ fund lists
Chief Chris Hill and three others waive awards after suspension of Equity Income fund
A more detailed riposte is needed to Carson Block’s claim
Commitments upon commitments.
Interest rates, Woodford under fire, Lloyds PPI blow
The investment manager might have to stump up £45m, but how?
Exchange demands cancellation of Benevolent AI, Industrial Heat and Ombu holdings
Manager’s investment trust does not have same problems as equity income fund
Investors in £3.5bn flagship income fund locked in until December
Role of authorised corporate director is fraught with potential for conflicts of interest
Eight funds assessed as exceeding the SEC’s 15 per cent cap in MSCI study
Questions raised why council fund did not have a segregated mandate and pulled cash in one go
Changes suggest fund manager will revert to a retail-only contrarian value approach
Will Deer, head of institutional sales at Woodford IM, made redundant
Tobacco group’s change in dividend policy gives investors option to hold or sell
UK biotech company hopes to challenge US dominance of gene sequencing market
More than $30bn pulled so far in 2019 as stockpicking comes under intense scrutiny
